Clinical data
AHFS/ International Drug Names
Routes of
ATC code C07AB06 (WHO)
Legal status
Legal status
  • unapproved, never marketed
CAS Number 59170-23-9 YesY
PubChem (CID) 2372
DrugBank DB01295 YesY
ChemSpider 2282 YesY
ChEBI CHEBI:238698 YesY
Chemical and physical data
Formula C20H27NO4
Molar mass 345.43 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.[1][2] It was discovered and developed by Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]


  1. Frishman, WH; Goldberg, RJ; Benfield, P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.". Drugs. 35 (1): 1–21. PMID 2894292.
  2. Vaughan Williams, EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.". Journal of clinical pharmacology. 27 (7): 450–60. PMID 2888789.
  3. McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia. (3rd ed. ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563.
  4. "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.
  5. Wong, GW; Boyda, HN; Wright, JM (10 March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.". The Cochrane database of systematic reviews. 3: CD007451. PMID 26961574.

This article is issued from Wikipedia - version of the 11/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.